Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle

Artemisin combination therapy (ACT) is the main treatment option for malaria, which is caused by the intracellular parasite Plasmodium. However, increased resistance to ACT highlights the importance of finding new drugs. Recently, the aspartic proteases Plasmepsin IX and X (PMIX and PMX) were identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Favuzza, Paola, de Lera Ruiz, Manuel, Thompson, Jennifer K., Triglia, Tony, Ngo, Anna, Steel, Ryan W.J., Vavrek, Marissa, Christensen, Janni, Healer, Julie, Boyce, Christopher, Guo, Zhuyan, Hu, Mengwei, Khan, Tanweer, Murgolo, Nicholas, Zhao, Lianyun, Penington, Jocelyn Sietsma, Reaksudsan, Kitsanapong, Jarman, Kate, Dietrich, Melanie H., Richardson, Lachlan, Guo, Kai-Yuan, Lopaticki, Sash, Tham, Wai-Hong, Rottmann, Matthias, Papenfuss, Tony, Robbins, Jonathan A., Boddey, Justin A., Sleebs, Brad E., Sabroux, Hélène Jousset, McCauley, John A., Olsen, David B., Cowman, Alan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146544/
https://www.ncbi.nlm.nih.gov/pubmed/32109369
http://dx.doi.org/10.1016/j.chom.2020.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146544/
https://www.ncbi.nlm.nih.gov/pubmed/32109369
http://dx.doi.org/10.1016/j.chom.2020.02.005

Ejemplares similares